Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects

Drug approval for early-stage breast cancer (EBC) has been historically granted in the context of registration trials based on adequate outcomes such as disease-free survival and overall survival. Improvements in long-term outcomes have made it more difficult to demonstrate the clinical benefit of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gion, María, Pérez-García, José Manuel, Llombart-Cussac, Antonio, Sampayo-Cordero, Miguel, Cortés, Javier, Malfettone, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640314/
https://www.ncbi.nlm.nih.gov/pubmed/34868353
http://dx.doi.org/10.1177/17588359211059587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640314/
https://www.ncbi.nlm.nih.gov/pubmed/34868353
http://dx.doi.org/10.1177/17588359211059587

Ejemplares similares